We observed increased tTG immunoreactivity and colocalization with Ab in the vessel wall in early stage CAA, whereas in later CAA stages, tTG and its cross-links were present in halos enclosing the Ab deposition. In CAA, tTG and its cross-links at the abluminal side of the vessel were demonstrated to be either of astrocytic origin in parenchymal vessels, of fibroblastic origin in leptomeningeal vessels, and of endothelial origin at the luminal side of the deposited Ab. Furthermore, the ECM proteins fibronectin and laminin colocalized with the tTG-positive halos surrounding the deposited Ab in CAA. However, we observed that in situ tTG activity was present throughout the vessel wall in late stage CAA. Together, our data suggest that tTG and its activity might play a differential role in the development and progression of CAA, possibly evolving from direct modulation of Ab aggregation to cross-linking of ECM proteins resulting in ECM restructuring.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by deposition of amyloid-beta (Ab) peptide aggregates in the brain. In the parenchyma, Ab aggregates in the form of senile plaques (SPs), whereas Ab deposition in the vasculature results in cerebral amyloid angiopathy (CAA) (Selkoe, 1994) . The Ab protein is a proteolytic cleavage product of the amyloid precursor protein and is produced in 2 major forms (Ab 1e40 and Ab 1e42 ), both capable of interacting with themselves which results in toxic Ab aggregates (Walsh et al., 1999) . SPs mainly consist of Ab 1e42 , whereas Ab 1e40 is the major component of CAA (Attems et al., 2011) . CAA is present in more than 90% of all AD patients (Jellinger and Attems, 2005) and is also the major pathologic hallmark in patients with hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D). HCHWA-D is characterized by the E22Q mutation in the amyloid precursor protein gene that results in a highly toxic form of Ab (i.e., D-Ab 40 ) which accumulates preferentially in brain vessel walls and leads to severe cerebral hemorrhaging (MaatSchieman et al., 2005) . Importantly, the presence of CAA does correlate with cognitive decline of CAA-affected patients (Attems et al., 2011; Greenberg et al., 2004) . In general, 2 types of CAA have been identified: type I CAA includes capillary Ab depositions in addition to CAA in other cortical and leptomeningeal vessels, whereas in type II CAA, capillary Ab depositions are not present (Thal et al., 2002a) . CAA is characterized by degeneration of smooth muscle cells, disruption of the basement membrane, and remodeling of extracellular matrix (ECM) (Attems et al., 2011; Perlmutter and Chui, 1990; Zipfel et al., 2009) . Together, these alterations lead to weakening of the vessel wall, impaired vascular functioning and, ultimately, hemorrhages (Attems et al., 2011; Zipfel et al., 2009) . Despite the strong connection between cognitive decline, reduced functioning of brain vasculature, and CAA, the factors and mechanisms underlying accumulation and deposition of Ab in the vessel wall remain largely unknown.
Tissue transglutaminase (tTG) is a member of the transglutaminase family (TGs; EC 2.3.2.13) and is ubiquitously expressed in the human brain (Kim et al., 1999; Wilhelmus et al., 2009) . tTG is a calcium-dependent enzyme involved in covalent posttranslational modifications of proteins such as amine incorporation and molecular cross-linking (Lorand and Graham, 2003) .
The latter is formed by the formation of a g-glutamyl-ε-lysine bond between a glutamine residue and a lysine residue of a peptide chain, which can be either intra-or intermolecular (Fesus and Piacentini, 2002; Griffin et al., 2002; Lorand and Graham, 2003) . This cross-linking activity provides tTG with the powerful capacity to stably alter conformation of proteins and induce formation of protein complexes (Lorand and Graham, 2003) . An important biological role of this cross-linking activity is formation of ECM protein complexes, which results in remodeling of the ECM in response to, e.g., cell stress and tissue injury (Bakker et al., 2005; Griffin et al., 2002; Ientile et al., 2007) . Evidence is mounting that tTG and its transamidation activity play an important role in AD pathogenesis (Wilhelmus et al., 2008) . In AD brain, tTG levels and its cross-links are elevated (Appelt et al., 1996; Johnson et al., 1997; Wang et al., 2008b) and correlate with the cognitive decline observed in these patients (Sárvári et al., 2002; Wang et al., 2008b) . Furthermore, tTG binds to Ab, and tTG-mediated cross-linking modulates the Ab aggregation pathway (Dudek and Johnson, 1994; Ikura et al., 1993; Rasmussen et al., 1994; Schmid et al., 2011) . In fact, a recent study demonstrated that tTG activity is able to induce formation of neurotoxic and protease resistant Ab complexes at low, i.e., nanomolar, concentrations of Ab (Hartley et al., 2008) .
We recently demonstrated for the first time that not only tTG, but also tTG-mediated cross-links are associated with the pathologic hallmarks of AD (Wilhelmus et al., 2009) . Interestingly, in this study we found that tTG and its cross-links are associated with both SPs and CAA; however, the distribution pattern of tTG and its activity in both lesions appeared different (Wilhelmus et al., 2009) . In SPs, immunoreactivity of both tTG and its cross-links colocalized with the deposited Ab, in contrast to CAA where no spatial overlay was observed. Instead, in CAA, tTG and its cross-links were present as a luminal and abluminal halo which enclosed the deposited Ab in middle-sized parenchymal vessels (Wilhelmus et al., 2009) . Remarkably, the tTG-immunoreactive halos that surround the deposited Ab, resembled that of earlier immunohistochemical stainings of major ECM proteins (i.e., fibronectin
[FN] and laminin [LN] ), and other known tTG substrates reported by others (Miners et al., 2008; van Duinen et al., 1995; Zhang et al., 1998) . These results suggest a role for tTG-mediated ECM remodeling in CAA which might be one of the unknown factors that affect Ab deposition in the vessel wall and CAA development (Wilhelmus et al., 2012) .
To gain more insight into the role of tTG and its transamidation activity in CAA, we studied the distribution pattern and cellular source of tTG and its cross-links in different brain vessels affected by CAA by use of immunofluorescence on snapfrozen brain tissue of AD, HCHWA-D, and control cases. In addition, we investigated colocalization of tTG and its cross-links with ECM proteins, in particular the tTG substrates FN and LN (Griffin et al., 2002; Zemskov et al., 2006) , in both AD and HCHWA-D brains. Finally, we also investigated the distribution pattern and overlay of in situ TG activity with CAA in control, AD, and HCHWA-D cases.
Methods

Brain tissue
Human neocortex tissue samples from 5 AD patients with CAA, including 2 patients with capillary CAA (age 83.8 AE 11.8 years; postmortem interval 8.0 AE 2.2 hours) and 7 nondemented control subjects without neurological disease including 2 control subjects with CAA (age 81.4 AE 4.7 years; postmortem interval 6.6 AE 1.5 hours) were obtained from The Netherlands Brain Bank (Amsterdam, The Netherlands). Brain tissue of the neocortex from 5 HCHWA-D patients (age 55.2 AE 4.0 years; postmortem interval 4.4 AE 1.1 hours) was obtained from Dr S. van Duinen (Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands). After autopsy, samples were immediately frozen in liquid nitrogen. Table 1 shows an overview of patient details including sex, age, postmortem interval, diagnosis, cause of death, Braak grading (for neurofibrillary tangles and SPs), and CAA score. The diagnosis of AD was based on neuropathologic and clinical criteria (Braak et al., 2006; Thal et al., 2002b) . CAA scoring was performed as described previously (Wilhelmus et al., 2009) : the number of CAA-affected vessels of at least 4 microscopic fields (magnification 4Â, 16 mm 2 per microscopic field) were counted and classified as follows: 0 (-, no CAA), 1e10 (þ, sparse CAA), 11e20 (þþ, moderate CAA) and > 21 (þþþ, severe CAA). Grading of AD (Braak) and of CAA was performed as described in the Methods section.
Double immunofluorescence
Experiments were performed as described previously (Wilhelmus et al., 2009 (Wilhelmus et al., , 2011a (Wilhelmus et al., , 2011b . Serial sections of temporal neocortex (6 mm) were fixed with acetone (100%) for 10 minutes and blocked with 3% bovine serum albumin (BSA; PAA Laboratories, Pasching, Austria) in Tris buffered saline (TBS) with 0.5% Triton X-100 (TBS-T). Negative controls were incubated in this solution without the primary antibodies. Primary antibodies (Table 2) were diluted in 3% BSA/TBS-T and incubated overnight at 4 C. After washing with TBS, sections were incubated with the appropriate secondary antibody. Secondary antibodies used were donkey antimouse, donkey anti-goat, and donkey anti-rabbit, all coupled to Alexa 488 or Alexa 594, (dilution 1:400, Invitrogen, Camarillo, CA, USA). Biotin-labeled donkey anti-mouse-IgM (dilution 1:800, Jackson Immunoresearch Laboratories Inc., West Grove, PA, USA) was used for the tTG crosslink antibody (81D4) and staining was enhanced with the Vectastain avidin-biotin kit (dilution 1:800 in TBS-T, Vector Laboratories Inc., Burlingame, CA, USA). As a second enhancement step for the 81D4 antibody, biotinylated tyramide in 0.005% H 2 O 2 -TBS was used (generous gift from Dr I. Huitinga, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands). The conjugate streptavidin Alexa 488 (Invitrogen) was used as a fluorchrome for the 81D4 antibody; streptavidin Alexa 594 was used as a secondary antibody for biotin-labeled mouse anti-human Ab antibody. In between incubation steps, sections were extensively washed with TBS. Sections were mounted with Vectashield (Vector Laboratories Inc.). The specificity of the antibodies directed against tTG in human brain was demonstrated in our previous reports (Wilhelmus et al., 2009 (Wilhelmus et al., , 2011b . The specificity of the anti-TG catalyzed cross-link antibody was demonstrated by preadsorption with H-Glu(H-Lys-OH)-OH (Bachem AG, Bubendorf, Switzerland) in human brain tissue (Wilhelmus et al., 2009) . To visualize the fluorescence stainings, a Leica TCS SP2 AOBS confocal laser scanning microscope (Leica Microsystems, Rijswijk, The Netherlands) was used. To exclude false positive fluorescence signals for each channel, a series of images was obtained separately in both channels through a 40Â lens (zoom factor 1Â to 4Â, Z-increment 0.15 mm, approximately 20 images of 512 Â 512 pixels).
In situ TG activity
In situ TG activity detection was performed as described previously (Jin et al., 2011) , with some minor changes. In brief, unfixed 6-mm thick tissue sections of neocortex of AD, HCHWA-D, and control patients were preincubated for 30 minutes at room temperature in a 100 mM Tris-HCl, pH 7.4, 5mM CaCl 2 , 1 mM dithiothreitol (Promega, Leiden, The Netherlands) buffer with or without 100 mM of the tTG activity inhibitor Z-DON-Val-Pro-LeuOMe (Z-006) (Schaertl et al., 2010) , purchased from Zedira GmbH, Darmstadt, Germany. Then, incubation was continued for 40 minutes at 37 C with the same incubation buffer with or without inhibitor to which 0.05 mM biotinylated 5-(biotinamido)-pentylamine (BAP; Thermo Fisher Scientific, Fremont, CA, USA), a substrate for TGs (Jeon et al., 1989; Lee et al., 1988) , was added. Thereafter, sections were washed with Milli-Q water, air-dried, fixed for 10 minutes with 100% acetone and subsequently incubated with a primary antibody directed against tTG (Ab1, Neomarkers) in 3% BSA/TBS-T for 1 hour at room temperature followed by 1 hour incubation at room temperature with secondary antibodies donkey anti-rabbit coupled to Alexa 594 to detect tTG (dilution 1:400) and streptavidin coupled to Alexa 488 to detect BAP incorporation (dilution 1:400). Sections were washed with TBS in between and after antibody incubation and mounted with Vectashield. The Leica TCS SP2 AOBS confocal laser scanning microscope was used to visualize the staining as described above.
Results
Distribution pattern of tTG and its cross-links in CAA of control, AD, and HCHWA-D cases
The general staining pattern of tTG and TG-catalyzed cross-links observed in the neocortex of control and AD cases are in line with our previous findings (Wilhelmus et al., 2009 ). Thus, in vessels of control cases and non-CAA affected vessels in AD and HCHWA-D cases, tTG staining was present in all layers of the vessel wall in leptomeningeal and parenchymal vessels (Fig. 1AeC, arrow) , and in capillaries. In addition, weak anti-tTG cross-link immunoreactivity was observed in all layers of the vessel wall in leptomeningeal and parenchymal vessels, predominantly at the endothelial side of the vessel wall (not shown). In CAA of AD cases, no spatial overlay of anti-tTG immunoreactivity with anti-Ab staining was observed (Fig. 1AeC) . However, tTG staining was present as a halo at both the luminal and abluminal side of deposited Ab, in parenchymal vessels (Fig. 1AeC) , leptomeningeal vessels (Fig. 1DeF) , and in capillaries (Fig. 1GeI) . Similar to tTG immunoreactivity in CAA, tTG cross-link staining was present in an abluminal and/or luminal halo surrounding Ab deposition in leptomeningeal and parenchymal vessels (Fig. 1JeL) , but only in an abluminal halo in capillary CAA (Fig. 1MeO) . In CAA present in nondemented control cases, a similar staining pattern for both tTG and its cross-links was observed (not shown). Interestingly, in probable CAA precursors, observed in the form of local Ab deposition in a large parenchymal vessel (Fig. 2AeC ) and a capillary vessel (Fig. 2DeF ) of AD cases, anti-tTG immunoreactivity was elevated compared with the unaffected part of the vessel, and, in contrast to the fully developed CAA, spatially colocalized with the deposited Ab.
To investigate whether the appearance of tTG and its cross-links as halos surrounding CAA might be a general phenomenon in CAA, we performed the above-described stainings in HCHWA-D patients. The distribution of tTG ( Fig. 3 ) and cross-links (not shown) in CAA in HCHWA-D cases was similar to CAA in AD cases, although tTG staining was more intense as compared with AD. . Double immunofluorescence staining of the anti-Ab antibody with either the anti-tTG (Ab1) or anti-transglutaminase-catalyzed cross-link antibody was performed. In Alzheimer's disease cases, tTG staining was observed in control vessels (A, arrow). In CAA however, tTG staining was observed in an abluminal and luminal halo enclosing the Ab deposition in both parenchymal (AeC) and leptomeningeal (DeF) vessels. In capillary CAA, tTG (Ab1 antibody) was present in an abluminal halo (GeI). Anti-tTG cross-link immunoreactivity was present at the abluminal and luminal side of the Ab deposition in larger cortical vessels (JeL) and at the abluminal side of capillary CAA (MeO). Scale bars: B, E, H, K, and N, 30 mm.
Colocalization of tTG with cellular markers in CAA of AD cases
To investigate the cellular origin of the observed tTG staining enclosing the deposited Ab in CAA, double immunofluorescence staining of tTG with cell-specific markers (glial fibrillary acidic protein, [GFAP] for astrocytes, Sofroniew and Vinters, 2010; von Willebrand Factor [VWF] for endothelial cells, Girma et al., 1987 , Jaffe et al., 1974 ; vimentin for fibroblasts, Franke et al., 1978 ; and smooth muscle actin [SMA] for smooth muscle cells, Skalli et al., 1987) was performed. Control cases, weak tTG staining was observed in astrocytes associated with brain vessels (Fig. 4AeC) . In CAA of AD cases however, strong anti-tTG immunoreactivity was observed in GFAP-positive astrocytes at the abluminal side of CAA in parenchymal vessels (Fig. 4DeF) . Especially the astrocytic end feet demonstrated strong tTG staining in CAA (Fig. 4DeF) . In CAA of leptomeningeal vessels tTG colocalized partly with vimentin, a marker for fibroblasts, in the abluminal halo (Fig. 4GeI) . Double immunofluorescence staining of tTG immunoreactivity with the anti-VWF antibody in control cases and in non-CAA affected vessels of AD cases, demonstrated tTG staining in all layers of the vessel wall, which at the luminal side colocalized with endothelial cells (not shown). In CAA of AD cases the luminal halo of tTG colocalized with endothelial cells, in both parenchymal (Fig. 4JeL) and leptomeningeal vessels (not shown). SMA staining was present in all layers of the vessel wall in control vessels where it colocalized with tTG (not shown). However, although SMA staining was present in all layers of vessels affected by CAA, no colocalization with tTG was observed (Fig. 4MeO) .
In HCHWA-D cases, like the AD staining, tTG and its cross-links colocalized with the astrocyte marker GFAP in astrocytic end feet at the abluminal side of Ab in parenchymal vessels, and with the endothelial marker VWF at the luminal side of Ab (not shown).
3.3. Colocalization of tTG and its cross-links with ECM proteins in CAA of AD cases tTG plays an important role in modulation of the ECM by crosslinking of ECM proteins (Griffin et al., 2002; Zemskov et al., 2006) . As demonstrated previously, several ECM proteins are associated with CAA, but do not spatially colocalize with the actual Ab deposition itself (Miners et al., 2008; van Duinen et al., 1995; Zhang et al., 1998) . Interestingly, the staining pattern of these ECM proteins resembles that of tTG and cross-links in CAA, as described in this study. Together, these data suggested that tTG might cross-link the Fig. 2 . Double immunofluorescence staining of tissue transglutaminase (tTG) with amyloid-beta (Ab) in vessels partly affected by Ab deposition. In a large parenchymal vessel (AeC) and capillary vessel (DeF), the anti-Ab antibody (AB10 and 715800, respectively) stained the Ab deposition (B and E). The anti-tTG antibody (06471 and Ab-1, respectively) showed a strong immunoreactivity in the Ab-affected part of the vessel compared with the nonaffected part of the blood vessel. In addition, tTG staining colocalized with the Ab staining (AeF, arrows). Scale bars: B, 30 mm; E, 15 mm. The anti-glial fibrillary acidic protein (GFAP) antibody stained astrocytes in parenchymal vessels (B and E), whereas the anti-vimentin antibody stained fibroblasts in the adventitia of the vessel wall of leptomeningeal vessels (H). The anti-Von Willebrand Factor (VWF) antibody stained endothelial cells in blood vessels (K) and the anti-smooth muscle actin (SMA) antibody stained smooth muscle cells in the media of the vessel wall (N). Double immunofluorescence staining of the anti-tTG (Ab1) antibody with either the anti-GFAP or anti-VWF antibody and double immunofluorescence of the anti-tTG (06471) antibody with either the anti-vimentin or anti-SMA antibody was performed. In control vessels, sporadic colocalization of tTG staining with GFAP staining was observed (AeC). In parenchymal CAA vessels, tTG staining in the abluminal halo (D) colocalized with the GFAP staining in astrocytic end feet (E and F). In leptomeningeal CAA vessels, tTG in the abluminal halo (G) colocalized with the vimentin staining (H and I, arrow). The tTG staining in the luminal halo (J) in CAA vessels colocalized with the anti-VWF antibody (K and L). tTG in the abluminal and luminal halo surrounding CAA did not spatially colocalize with SMA staining (MeO). Scale bars: B, H, K, and N, 30 mm; E, 15 mm. Vaheri, 1978) . In CAA in AD cases, elevated anti-FN and anti-LN immunoreactivity was found as an abluminal and/or luminal halo enclosing the deposited Ab ( Fig. 5B and E) . In addition, both the anti-FN and anti-LN immunoreactivity colocalized with tTG ( Fig. 5AeC and DeF, respectively) and tTG cross-link staining ( Fig. 6AeC and DeF, respectively). In CAA of HCHWA-D cases, the distribution of FN and LN staining was similar to the AD cases, showing an abluminal and/or luminal halo that spatially colocalized with the anti-tTG antibody (Fig. 5GeI and JeL, respectively).
In situ TG activity in CAA in AD and HCHWA-D cases
We observed that tTG staining was present in the Ab part of CAA precursors, whereas in later stages of CAA, tTG was not present in the Ab deposition. Epitope masking of tTG might have caused this lack of staining. In addition, the conformation of tTG, which is an important property of the enzyme that influences its function (Pinkas et al., 2007) , might affect the recognition by the antibodies we used. Therefore, to investigate whether tTG is still present and active in the Ab part of CAA, we investigated the in situ activity of TGs by the incorporation of the TG substrate BAP. Snap frozen tissue sections of the neocortex of AD, HCHWA-D, and control cases were incubated with the TG substrate BAP and stained for the presence of tTG and BAP. In vessels of control cases and non-CAA affected vessels in AD and HCHWA-D cases, weak BAP staining was observed in all layers of the vessel wall which colocalized with tTG staining (Fig. 7AeC) . After coincubation with the specific tTG inhibitor Z-006, no BAP staining was detectable, in contrast to the tTG staining, which remained unaffected (Fig. 7DeF) . In CAA in AD and HCHWA-D cases, however, BAP staining was remarkably increased compared with control vessels, and was present in all layers of the vessel wall (Fig. 7G) . In addition, BAP staining also colocalized with the typical tTG halos enclosing the Ab part of CAA (Fig. 7GeI,  arrow) . After coincubation with the specific tTG inhibitor Z-006, no BAP staining was detectable in CAA, whereas tTG staining was still present in the two halos surrounding the deposited Ab (Fig. 7JeL) . 
Discussion
In this study, we describe for the first time that immunoreactivity of tTG in a vessel wall partly affected by Ab deposition, which might indicate an early stage, is increased and colocalizes with the deposited Ab. In contrast, in later stages of CAA, both tTG and its cross-links no longer colocalize with the deposited Ab, but are present in an abluminal and luminal halo enclosing the Ab deposition. We observed that the abluminal halo of parenchymal vessels in CAA are of astrocytic origin and that tTG might derive from fibroblasts in leptomeningeal vessels, whereas tTG in the luminal halo in all vessel types is of endothelial origin. Furthermore, tTG substrates and important ECM components FN and LN colocalize with tTG and its cross-links in the halos that enclose Ab deposition in CAA. We observed this distribution pattern of tTG and its crosslinks in CAA in nondemented control, AD, and HCHWA-D cases, which suggests that this pattern is a general phenomenon of CAA. Surprisingly however, although we did not observe tTG and tTG cross-link staining in the actual Ab deposition in CAA, we found that tTG is still present and could be activated in situ in the deposited Ab. Together our data suggest that tTG plays a unique role in CAA development and progression. Initially, tTG levels are elevated in early stages of CAA, and might even precede Ab deposition, whereas in later stages tTG is likely to be involved in alteration and/or remodeling of the ECM in CAA.
Previously, we noticed an important discrepancy between the distribution pattern of tTG and its cross-links in SPs and CAA. tTG and its cross-links colocalized with the deposited Ab in both diffuse and classic SPs, whereas in CAA, tTG and its cross-links did not colocalize with the Ab aggregate itself (Wilhelmus et al., 2009) . Instead, in CAA, both tTG and its cross-links were present in an abluminal and luminal halo enclosing the Ab deposition in middlesized parenchymal vessels with CAA in AD patients (Wilhelmus et al., 2009) . In the present study, we found that apart from middle-sized parenchymal vessels affected by CAA in AD cases, tTG and its cross-links enclose the Ab deposition in all parenchymal vessels and leptomeningeal vessels, as well as in capillaries affected by CAA. In addition, tTG and its cross-links were present in a similar distribution pattern in CAA in HCHWA-D cases and in CAA-affected vessels of nondemented control cases. Together, these findings point out that the presence of tTG and cross-links in halos that enclose Ab is a common phenomenon found in type I and type II CAA (with or without capillary CAA respectively), in different diseases that are characterized by CAA, and even in CAA in nondemented control cases.
Interestingly, in a parenchymal and capillary vessel only partly affected by CAA, which might indicate an early stage of CAA development, tTG was present in the Ab deposition itself. In later stages of CAA, tTG and its cross-links did not colocalize with Ab, although tTG could still be activated with our in situ assay in both the Ab part of CAA and the tTG-immunoreactive halos enclosing the Ab. However, it should be noted that although it is highly likely that our in situ approach demonstrates tTG activity, this technique might also activate other TGs. However, although both TG1 and TG3 are present in the human brain, there is no association of these TGs with cerebral vessels or CAA (Kim et al., 1999; Wilhelmus et al., 2009) . In addition, the potent tTG inhibitor Z-006 that was used in our experiments could inhibit other TGs, yet it has a significantly higher affinity for tTG compared with other TGs (Schaertl et al., 2010) . Together we therefore conclude that tTG is present in CAA in early and later stages and that its activity might have a unique role in Ab deposition and development of CAA.
In early stages of CAA development, Ab accumulates in the media around the vascular smooth muscle cells (Attems et al., 2011) . We observed tTG immunostaining in the Ab deposition itself in vessels partly affected by CAA. In this stage of CAA, tTG might originate from smooth muscle cells, because these cells are known to produce and secrete tTG (Greenberg et al., 1991; van den Akker et al., 2012) . A similar tTG staining was present in capillaries suggesting that pericytes are the cellular source in capillaries. Hence, endothelial cells are also known to produce tTG (Thomazy and Fesus, 1989) . Although the cellular origin of tTG in capillaries and larger vessels might differ, tTG staining in the Ab deposition was increased compared with the non-CAA affected part of the vessel wall. This suggests that either tTG levels are elevated in response to the Ab deposition in the vessel wall, or that induced tTG levels and activity result in Ab deposition in the vessel wall. An in vitro study has shown that tTG is upregulated in a monocytic cell line after treatment with Ab 1e42 (Curro et al., 2010) . Furthermore, tTG can cross-link Ab and affect its aggregation pathway (Dudek and Johnson, 1994; Hartley et al., 2008; Ikura et al., 1993; Rasmussen et al., 1994; Schmid et al., 2011) . Therefore, in vivo tTG expression might be increased in response to Ab deposition in the vessel wall, which might lead to Ab cross-linking in the initial stages of CAA. On the contrary, increased levels of tTG might also precede Ab deposition. tTG is normally present in the vessel wall, where it is important in cross-linking of ECM proteins leading to remodeling of the vessel wall (Bakker et al., 2005) . Levels of tTG in the vasculature increase with age, which leads to enhanced ECM cross-linking and subsequent vascular stiffness (Santhanam et al., 2010) . These changes in the vessel wall might influence Ab deposition. In addition, several proteins that are known to affect the Ab cascade, in particular heparan sulphate proteoglycans and small heat shock protein B2 (Wilhelmus et al., 2006 (Wilhelmus et al., , 2007 , are also substrates for tTG (Boros et al., 2006; Verderio et al., 2009 ). The fact that these tTG substrates are present in CAA as well suggests that tTG activity might affect Ab aggregation and deposition, either directly or via cross-linking of Ab chaperones. However, the role of tTG in initial stages of CAA remains to be investigated, and the use of in vivo models, in particular animal models of CAA, will be instrumental for this purpose.
In late stages of CAA, we found that tTG staining in the abluminal halo was of astrocytic origin in parenchymal vessel and derived from fibroblasts in leptomeningeal vessels, whereas tTG was of endothelial origin in the luminal halo. All these cell types are known to produce tTG (Bakker et al., 2008; Nurminskaya and Belkin, 2012; Yamada et al., 1998; Zemskov et al., 2006) , and tTG is upregulated in response to cell stress and inflammation (Wang et al., 2008a) . Ab deposition is suggested to precede inflammation (Heneka et al., 2010) , thus expression of tTG might be increased especially in the cells surrounding the Ab deposition in CAA. In parenchymal vessels, fibroblasts might produce tTG as well, although we could not distinguish astrocytes from fibroblasts, as vimentin stains mesenchymal cells including astrocytes and Fig. 7 . In situ transglutaminase activity. Double immunofluorescence was performed with the anti-tissue transglutaminase (tTG) antibody (Ab1) and streptavidin coupled to Alexa 488 directed against the biotin-label of biotinylated 5-(biotinamido)-pentylamine (BAP). In non-cerebral amyloid angiopathy (non-CAA) vessels of Alzheimer's disease cases, weak staining of both BAP and tTG was observed in all layers of the vessel wall (AeC). In addition, BAP and tTG staining colocalized in all layers of the vessel wall (AeC). Coincubation of the specific tTG inhibitor Z-006 (100 mM) with BAP resulted in absence of BAP staining in the control vessel (D). In cerebral amyloid angiopathy (CAA), strong BAP staining was observed in all layers of the vessel wall (G), whereas no BAP staining was present after coincubation with Z-006 (100 mM) (J). tTG was again present in an abluminal and luminal halo surrounding the amyloid-beta deposition in CAA (H and K). Colocalization of BAP with tTG staining was observed in CAA (GeI, arrows). Scale bar: B and E, 15 mm; H and K, 30 mm.
fibroblasts. Taken together, although the tTG in CAA is likely to be derived from astrocytes, fibroblasts, and endothelial cells, a role in the production of tTG by smooth muscle cells, as in early stage CAA, cannot be excluded.
The presence and activity of tTG in the abluminal and luminal halo points toward a role in remodeling of the ECM. Altered expression of ECM proteins has already been observed in CAA and the brain microvasculature in AD (Kalaria, 1996; Miners et al., 2008; Perlmutter, 1994; Perlmutter and Chui, 1990; van Duinen et al., 1995; Zhang et al., 1998) . In our study we observed, in line with previous studies (Miners et al., 2008; van Duinen et al., 1995; Zhang et al., 1998) , altered expression of the ECM proteins FN and LN. Both FN and LN were present in an abluminal and/or luminal halo that surrounded the Ab deposition. We here found that FN and LN colocalized with tTG and its cross-links in CAA of AD and HCHWA-D patients, suggesting that tTG might cross-link these ECM proteins in CAA. The putative cross-linking of FN and LN by tTG might have detrimental effects, because excess production and cross-linking of ECM proteins in diabetic nephropathy is associated with renal fibrosis and scarring (Skill et al., 2004) . Furthermore, the formation of cross-linked proteins at the endothelial side of the vessel could impair transport of solutes and molecules across the blood-brain barrier leading to impaired supply of nutrients in the brain thus compromising brain functioning. In addition, tTG-mediated crosslinking of ECM proteins might stiffen the vessel wall, resulting in impaired clearance of Ab from the brain via the interstitial fluid drainage (Schley et al., 2006; Weller et al., 2009; Wilhelmus et al., 2012) . Furthermore, impaired clearance of Ab via this route might not only be the underlying cause of Ab accumulation in the vessel wall leading to CAA, but also contributes to the accumulation of Ab in the brain parenchyma (Weller et al., 2009) .
On the other hand, the cross-linked ECM proteins might have a protective effect in CAA, because this cross-linked barrier might prevent the weakening of the vessel wall (Zipfel et al., 2009 ) and leakage of the blood-brain barrier, possibly reducing the risk of hemorrhages which can be the result of CAA (Attems et al., 2011; Wisniewski et al., 1997; Zipfel et al., 2009 ). In addition, at the abluminal side, the cross-linked ECM proteins might serve as a barrier to prevent spreading of toxic Ab into the brain parenchyma. Clearly, further investigations are required to investigate these options.
In conclusion, we found that tTG immunoreactivity is increased in early stages of CAA where it colocalized with Ab deposition in the vessel wall, whereas tTG and its cross-links in more mature CAA lesions colocalized with ECM proteins in an abluminal and luminal halo enclosing the Ab deposition. The role of tTG in early stage CAA might therefore be different from end stage CAA, when tTGmediated ECM remodeling might be more important than its effect on Ab aggregation per se. However, because we observed an increased tTG transamidation activity in the Ab deposition also in end stage CAA lesions, this might be the consequence of epitope masking in these densely packed Ab depositions. Chronological evaluation of CAA lesion development in animal models of CAA will hopefully provide answers to the outstanding questions on the role of tTG in vascular pathology in AD and related disorders.
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